These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27927046)

  • 1. Advances in chemical pharmacotherapy to manage advanced breast cancer.
    Gombos A; Awada A
    Expert Opin Pharmacother; 2017 Jan; 18(1):95-103. PubMed ID: 27927046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal adjuvant chemotherapy in breast cancer: selection of agents.
    Esposito A; Criscitiello C; Salè EO; Curigliano G
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):605-11. PubMed ID: 25080998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
    Lumachi F; Chiara GB; Foltran L; Basso SM
    Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer.
    Martinello R; Genta S; Galizia D; Geuna E; Milani A; Zucchini G; Valabrega G; Montemurro F
    Expert Opin Pharmacother; 2016 Nov; 17(16):2179-2189. PubMed ID: 27646965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapeutic options for patients with refractory breast cancer.
    Fedele P; Ciccarese M; Surico G; Cinieri S
    Expert Opin Pharmacother; 2019 May; 20(7):851-861. PubMed ID: 30730767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of the intrinsic molecular subtypes of breast cancer.
    Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
    Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer.
    Nakatsukasa K; Koyama H; Oouchi Y; Imanishi S; Mizuta N; Sakaguchi K; Fujita Y; Fujiwara I; Kotani T; Matsuda T; Fukuda K; Morita M; Kawakami S; Kadotani Y; Konishi E; Yanagisawa A; Taguchi T
    Breast Cancer; 2017 Jan; 24(1):63-68. PubMed ID: 26754092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time for more optimism in metastatic breast cancer?
    Senkus E; Cardoso F; Pagani O
    Cancer Treat Rev; 2014 Mar; 40(2):220-8. PubMed ID: 24126121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
    Mestres JA; iMolins AB; Martínez LC; López-Muñiz JI; Gil EC; de Juan Ferré A; Del Barco Berrón S; Pérez YF; Mata JG; Palomo AG; Gregori JG; Pardo PG; Mañas JJ; Hernández AL; de Dueñas EM; Jáñez NM; Murillo SM; Bofill JS; Auñón PZ; Sanchez-Rovira P
    Clin Transl Oncol; 2017 Feb; 19(2):149-161. PubMed ID: 27314861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes.
    Menes TS; Golan O; Vainer G; Lerman H; Schneebaum S; Klausner J; Even-Sapir E
    Clin Breast Cancer; 2016 Oct; 16(5):389-395. PubMed ID: 27282845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
    Manso L; Palomo AG; Pérez Carrión R; Cassinello J; Gallegos Sancho I; Chacón López-Muñiz I; Olier C; Fernández-Aramburo A; Llorca C; González X; Llorente R; Torregrosa D; Álvarez I; Gálve E; Bueno C; Garau I; García MJ; González-Santiago S; Ballesteros AI; Blanco E; Galán A; González S; Perelló A; Cortés-Funes H; Grávalos C
    Anticancer Res; 2015 Dec; 35(12):6941-50. PubMed ID: 26637920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
    von Minckwitz G; Schneeweiss A; Loibl S; Salat C; Denkert C; Rezai M; Blohmer JU; Jackisch C; Paepke S; Gerber B; Zahm DM; Kümmel S; Eidtmann H; Klare P; Huober J; Costa S; Tesch H; Hanusch C; Hilfrich J; Khandan F; Fasching PA; Sinn BV; Engels K; Mehta K; Nekljudova V; Untch M
    Lancet Oncol; 2014 Jun; 15(7):747-56. PubMed ID: 24794243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular subtype shift in breast cancer upon trastuzumab treatment: a case report.
    Āboliņš A; Vanags A; Trofimovičs G; Miklaševičs E; Gardovskis J; Štrumfa I
    Pol J Pathol; 2011; 62(1):65-8. PubMed ID: 21574108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
    Awada G; Gombos A; Aftimos P; Awada A
    Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
    Wood R; Mitra D; de Courcy J; Iyer S
    Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.